{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:48:36Z","timestamp":1788364116110,"version":"build-2803163510"},"reference-count":39,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tzu Chi Medical Foundation","award":["TCMF-MP-110-03-01"],"award-info":[{"award-number":["TCMF-MP-110-03-01"]}]},{"name":"Tzu Chi Medical Foundation","award":["TCMF-SP-112-01"],"award-info":[{"award-number":["TCMF-SP-112-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Purpose: Neurogenic lower urinary tract dysfunction (NLUTD) is common in patients with neurological lesions in the central nervous system (CNS). Medical treatment usually cannot adequately relieve NLUTD. This study reported the real-life treatment outcome of botulinum toxin A (BoNT-A) for overactive bladders (OAB) and voiding dysfunction in patients with CNS lesions. Methods: We retrospectively analyzed the first-time treatment outcome of 74 patients who received detrusor 100 U BoNT-A for OAB and 45 patients who received a urethral sphincter 100 U BoNT-A injection for voiding dysfunction. The treatment outcome, therapeutic duration, and adverse events (AE) after BoNT-A were compared among different CNS lesions and among patients with different urodynamic characteristics. Results: The study included 74 patients receiving detrusor injections for OAB (36 with cerebrovascular accidents, 13 with Parkinson\u2019s disease, and 25 with dementia) and 45 patients receiving a urethral sphincter injection for voiding dysfunction (26 with cerebrovascular accidents, 7 with Parkinson\u2019s disease, and 12 with dementia). After detrusor BoNT-A treatment, urinary continence was achieved in 28.4% of patients with neurogenic OAB, postoperative difficult urination in 59.5%, acute urinary retention (AUR) in 9.5%, and urinary tract infection (UTI) in 14.9%, with a therapeutic duration of 6.43 months. There were no differences among subgroups or between patients with detrusor overactivity (DO) and DO with detrusor underactivity (DU) in terms of treatment outcomes and AEs. The improvement rate of urethral sphincter BoNT-A injections was 75.6% without any difference among subgroups. After treatment, 24.4% of the patients had exacerbated urinary incontinence, 33.3% had persistent difficult urination, and 15.6% had UTI. Patients with dementia had higher rates of difficult urination and UTI, higher postvoid residual volume, and a shorter therapeutic duration. Patients with DU and those without urethral sphincter dyssynergia had less favorable outcomes after their urethral sphincter BoNT-A injection. Conclusions: The therapeutic efficacy of detrusor BoNT-A injection for OAB due to CNS lesions is limited, with high rates of difficult urination, AUR, and UTI. Although urethral sphincter BoNT-A injection is effective in treating voiding dysfunction; however, exacerbated urinary incontinence and persistent difficult urination remain a problem, particularly in patients with dementia.<\/jats:p>","DOI":"10.3390\/toxins16030123","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T03:31:23Z","timestamp":1709263883000},"page":"123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-Life Treatment Outcome of Botulinum Toxin A Injection on Overactive Bladder and Voiding Dysfunction in Patients with Central Nervous System Lesions"],"prefix":"10.3390","volume":"16","author":[{"given":"Yuan-Hong","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Fong","family":"Jhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1761-1185","authenticated-orcid":false,"given":"Sheng-Fu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/01.ju.0000177450.34451.97","article-title":"Brain control of normal and overactive bladder","volume":"174","author":"Griffiths","year":"2005","journal-title":"J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s00415-016-8212-2","article-title":"Neurogenic lower urinary tract dysfunction: Evaluation and management","volume":"263","author":"Tudor","year":"2016","journal-title":"J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/ageing\/23.3.246","article-title":"Cerebral aetiology of urinary urge incontinence in elderly people","volume":"23","author":"Griffiths","year":"1994","journal-title":"Age Ageing"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.46.3.682","article-title":"Temporal pattern of cognitive decline and incontinence is different in Alzheimer\u2019s disease and diffuse Lewy body disease","volume":"46","author":"Munoz","year":"1996","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1464-410X.2007.06754.x","article-title":"Post-stroke urinary incontinence with impaired awareness of the need to void: Clinical and urodynamic features","volume":"99","author":"Pettersen","year":"2007","journal-title":"BJU Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4081\/aiua.2022.4.492","article-title":"Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials","volume":"94","author":"Bapir","year":"2022","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.euf.2021.10.006","article-title":"Benefits and harms of conservative, pharmacological, and surgical management options for women with bladder outlet obstruction: A systematic review from the European Association of Urology Non-neurogenic Female LUTS Guidelines Panel","volume":"8","author":"Peyronnet","year":"2022","journal-title":"Eur. Urol. Focus."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/17425255.2016.1178239","article-title":"Pharmacologic management of non-neurogenic functional obstruction in women","volume":"12","author":"Cohn","year":"2016","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/nau.24879","article-title":"Botulinum toxin for treating overactive bladder in men: A systematic review","volume":"41","author":"Truzzi","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/NRE-2012-0721","article-title":"Post-CVA voiding dysfunctions: Clinical insights and literature review","volume":"30","author":"Linsenmeyer","year":"2012","journal-title":"NeuroRehabilitation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0022-5347(05)67048-6","article-title":"Voiding dysfunction and Parkinson\u2019s disease: Urodynamic abnormalities and urinary symptoms","volume":"164","author":"Araki","year":"2000","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5213\/jkcs.2008.12.1.10","article-title":"Dementia and voiding dysfunction","volume":"12","author":"Choi","year":"2008","journal-title":"J. Korean Cont. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ageing\/afs009","article-title":"Urinary symptoms and natural history of urinary continence after first-ever stroke\u2014A longitudinal population-based study","volume":"41","author":"Williams","year":"2012","journal-title":"Age Ageing"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0022-510X(95)00322-S","article-title":"Micturitional disturbance after acute hemispheric stroke: Analysis of the lesion site by CT and MRI","volume":"137","author":"Sakakibara","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/j.1532-5415.2006.00984.x","article-title":"Prognostic significance of micturition disturbances after acute stroke","volume":"54","author":"Pettersen","year":"2006","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJM199810153391607","article-title":"Parkinson\u2019s disease. Second of two parts","volume":"339","author":"Lang","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1464-410X.1983.tb03406.x","article-title":"Urethral sphincter abnormalities in Parkinsonism","volume":"55","author":"Galloway","year":"1983","journal-title":"Br. J. Urol."},{"key":"ref_23","first-page":"145","article-title":"Urinary dysfunctions and post-void residual urine in typical and atypical Parkinson diseases","volume":"8","author":"Lee","year":"2018","journal-title":"J. Park. Dis."},{"key":"ref_24","first-page":"654","article-title":"The connection between frontal lobe brain tumors and lower urinary tract symptoms\u2014Series of 347 patients","volume":"25","author":"Trakolis","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jiang, Y.H., Liao, C.H., Tang, D.L., and Kuo, H.C. (2014). Efficacy and safety of intravesical onabotulinumtoxinA injection on elderly patients with chronic central nervous system lesions and overactive bladder. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105989"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hu, J.C., Hsu, L.N., Lee, W.C., Chuang, Y.C., and Wang, H.J. (2023). Role of urological botulinum toxin-A injection for overactive bladder and voiding dysfunction in patients with Parkinson\u2019s disease or post-stroke. Toxins, 15.","DOI":"10.3390\/toxins15020166"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lee, H.Y., and Kuo, H.C. (2023). Intravesical injection of botulinum toxin type A in men without bladder outlet obstruction and post-deobstructive prostate surgery. Toxins, 15.","DOI":"10.3390\/toxins15030221"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/tcmj.tcmj_313_21","article-title":"The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis","volume":"35","author":"Jiang","year":"2023","journal-title":"Tzu Chi Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e32377","DOI":"10.1097\/MD.0000000000032377","article-title":"Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact","volume":"102","author":"Nitti","year":"2023","journal-title":"Medicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ucl.2017.04.012","article-title":"Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity","volume":"44","author":"Kaviani","year":"2017","journal-title":"Urol. Clin. North. Am."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/nau.23717","article-title":"Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson\u2019s disease","volume":"37","author":"Vurture","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.purol.2021.01.004","article-title":"Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson\u2019s disease","volume":"31","author":"Atamian","year":"2021","journal-title":"Prog. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.23869","article-title":"Management of neurogenic bladder in patients with Parkinson\u2019s disease: A systematic review","volume":"38","author":"Hajebrahimi","year":"2019","journal-title":"Neurourol. Urodyn."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/nau.25037","article-title":"SUFU white paper on overactive bladder anticholinergic medications and dementia risk","volume":"41","author":"Zillioux","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5213\/inj.2040354.177","article-title":"Frontiers in the clinical applications of botulinum toxin A as treatment for neurogenic lower urinary tract dysfunction","volume":"24","author":"Jiang","year":"2020","journal-title":"Int. Neurourol. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2013.09.017","article-title":"OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson\u2019s disease","volume":"83","author":"Anderson","year":"2014","journal-title":"Urology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.juro.2018.10.012","article-title":"Long-term discontinuation of botulinum toxin A intradetrusor injections for neurogenic detrusor overactivity: A multicenter study","volume":"201","author":"Baron","year":"2019","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/jnnp.2004.045765","article-title":"Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients","volume":"76","author":"Gallien","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/tcmj.tcmj_209_21","article-title":"Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly","volume":"35","author":"Kuo","year":"2023","journal-title":"Tzu Chi Med. J."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/3\/123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:33Z","timestamp":1760105253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/3\/123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["toxins16030123"],"URL":"https:\/\/doi.org\/10.3390\/toxins16030123","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}